Metric,Vaccine,Summary
Developer(s),Anhui Zhifei Longcom Biopharmaceutical ZF2001,"Anhui Zhifei Longcom Biopharmaceutical, Chinese Academy of Sciences"
Platform,Anhui Zhifei Longcom Biopharmaceutical ZF2001,Protein subunit
Dosing,Anhui Zhifei Longcom Biopharmaceutical ZF2001,"2/3 doses, intramuscular"
Description,Anhui Zhifei Longcom Biopharmaceutical ZF2001,Adjuvanted recombinant protein vaccine targeting SARS-CoV-2 receptor binding domain (RBD)
Published results,Anhui Zhifei Longcom Biopharmaceutical ZF2001,Phase I/II - see <b>Living review</b>
Efficacy data,Anhui Zhifei Longcom Biopharmaceutical ZF2001,Pending
Storage requirements,Anhui Zhifei Longcom Biopharmaceutical ZF2001,Pending - refrigeration (2°C to 8°C) is typical for protein subunit vaccines
"<a href=""https://www.one.org/international/vaccine-access-test/"" target=""_blank"">ONE Vaccine Access Test score</a>",Anhui Zhifei Longcom Biopharmaceutical ZF2001,No score available
Approval status,Anhui Zhifei Longcom Biopharmaceutical ZF2001,Emergency use in China and Uzbekistan
,,
Developer(s),Bharat Covaxin/BBV152,"Bharat Biotech, ICMR, National Institute of Virology"
Platform,Bharat Covaxin/BBV152,Inactivated
Dosing,Bharat Covaxin/BBV152,"2 doses, intramuscular"
Description,Bharat Covaxin/BBV152,Inactivated vaccine administered with imidazoquinoline adjuvant (TLR7/8 agonist)
Published results,Bharat Covaxin/BBV152,Phase I/II - see <b>Living review</b>
Efficacy data,Bharat Covaxin/BBV152,"Vaccine efficacy estimated to be 78% against symptomatic COVID-19 (based on 130 cases) and 93% against severe COVID-19 (based on 16 cases) in a preprint published on <a href=""https://www.medrxiv.org/content/10.1101/2021.06.30.21259439v1"" target=""_blank"">02 Jul 2021</a>)"
Storage requirements,Bharat Covaxin/BBV152,Refrigeration (2°C to 8°C)
"<a href=""https://www.one.org/international/vaccine-access-test/"" target=""_blank"">ONE Vaccine Access Test score</a>",Bharat Covaxin/BBV152,No score available
Approval status,Bharat Covaxin/BBV152,"Emergency use in India, Iran, and Zimbabwe"
,,
Developer(s),BioNTech/Pfizer BNT162b2,"BioNTech, Pfizer, Fosun Pharma"
Platform,BioNTech/Pfizer BNT162b2,RNA
Dosing,BioNTech/Pfizer BNT162b2,"2 doses, intramuscular"
Description,BioNTech/Pfizer BNT162b2,Lipid nanoparticle-formulated mRNA encoding full-length spike (S) protein
Published results,BioNTech/Pfizer BNT162b2,Phase I/II/III - see <b>Living review</b>
Efficacy data,BioNTech/Pfizer BNT162b2,Vaccine efficacy against COVID-19 of 95% based on primary efficacy analysis of 170 confirmed cases - see <b>Living review</b>
Storage requirements,BioNTech/Pfizer BNT162b2,Ultra-cold (-60°C to -80°C)
"<a href=""https://www.one.org/international/vaccine-access-test/"" target=""_blank"">ONE Vaccine Access Test score</a>",BioNTech/Pfizer BNT162b2,"BioNTech and Pfizer given scores of 3 and 9 out of 20, respectively"
Approval status,BioNTech/Pfizer BNT162b2,"Full or emergency use in numerous countries; granted emergency use approval by the WHO on <a href=""https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access"" target=""_blank"">31 Dec 2020</a>"
,,
Developer(s),Beijing/Sinopharm BBIBP-CorV,"Beijing Institute of Biological Products, Sinopharm"
Platform,Beijing/Sinopharm BBIBP-CorV,Inactivated
Dosing,Beijing/Sinopharm BBIBP-CorV,"2 doses, intramuscular"
Description,Beijing/Sinopharm BBIBP-CorV,Inactivated vaccine administered with aluminium hydroxide adjuvant
Published results,Beijing/Sinopharm BBIBP-CorV,Phase I/II/III - see <b>Living review</b>
Efficacy data,Beijing/Sinopharm BBIBP-CorV,Vaccine efficacy against COVID-19 of 78% based on interim efficacy analysis of 116 confirmed cases - see <b>Living review</b>
Storage requirements,Beijing/Sinopharm BBIBP-CorV,Refrigeration (2°C to 8°C)
"<a href=""https://www.one.org/international/vaccine-access-test/"" target=""_blank"">ONE Vaccine Access Test score</a>",Beijing/Sinopharm BBIBP-CorV,No score available
Approval status,Beijing/Sinopharm BBIBP-CorV,"Full or emergency use in numerous countries, including China, UAE, Bahrain, Egypt, and Hungary; granted emergency use approval by the WHO on <a href=""https://www.who.int/news/item/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations"" target=""_blank"">07 May 2021</a>"
,,
Developer(s),Cansino Ad5-nCoV,"CanSino Biological Inc, Beijing Institute of Biotechnology"
Platform,Cansino Ad5-nCoV,Non-replicating viral vector
Dosing,Cansino Ad5-nCoV,"1 dose, intramuscular"
Description,Cansino Ad5-nCoV,Ad5 vector containing full-length spike (S) protein
Published results,Cansino Ad5-nCoV,"Phase I, phase II - see <b>Living review</b>"
Efficacy data,Cansino Ad5-nCoV,"Vaccine efficacy of 66% against symptomatic COVID-19 and 91% against severe disease as reported by Pakistan's health minister on <a href=""https://www.reuters.com/article/us-health-coronavirus-vaccine-pakistan-idUSKBN2A81N0"" target=""_blank"">08 Feb 2021</a>); estimates based on 101 confirmed cases; full publication pending"
Storage requirements,Cansino Ad5-nCoV,Pending - refrigeration (2°C to 8°C) or freezing (-15°C to -25°C) is typical for vectored vaccines
"<a href=""https://www.one.org/international/vaccine-access-test/"" target=""_blank"">ONE Vaccine Access Test score</a>",Cansino Ad5-nCoV,No score available
Approval status,Cansino Ad5-nCoV,"Full or emergency use in China, Mexico, and Pakistan"
,,
Developer(s),CIGB CIGB-66/Abdala,"Center for Genetic Engineering and Biotechnology, Cuba"
Platform,CIGB CIGB-66/Abdala,Protein subunit
Dosing,CIGB CIGB-66/Abdala,"3 doses, intramuscular"
Description,CIGB CIGB-66/Abdala,RBD administered with aluminum hydroxide
Published results,CIGB CIGB-66/Abdala,None
Efficacy data,CIGB CIGB-66/Abdala,"Vaccine efficacy of 92% against COVID-19 based on reports by BioCubaFarma on <a href=""https://twitter.com/BioCubaFarma/status/1407113443304521728"" target=""_blank"">22 Jun 2021</a>); further details and full publication pending"
Storage requirements,CIGB CIGB-66/Abdala,Pending - refrigeration (2°C to 8°C) is typical for protein subunit vaccines
"<a href=""https://www.one.org/international/vaccine-access-test/"" target=""_blank"">ONE Vaccine Access Test score</a>",CIGB CIGB-66/Abdala,No score available
Approval status,CIGB CIGB-66/Abdala,Emergency use in Cuba
,,
Developer(s),Chumakov Center CoviVac,"Chumakov Center, Russian Academy of Sciences"
Platform,Chumakov Center CoviVac,Inactivated
Dosing,Chumakov Center CoviVac,"2 doses, intramuscular"
Description,Chumakov Center CoviVac,Inactivated whole-virion vaccine
Published results,Chumakov Center CoviVac,None
Efficacy data,Chumakov Center CoviVac,Pending
Storage requirements,Chumakov Center CoviVac,Pending - refrigeration (2°C to 8°C) is typical for inactivated vaccines
"<a href=""https://www.one.org/international/vaccine-access-test/"" target=""_blank"">ONE Vaccine Access Test score</a>",Chumakov Center CoviVac,No score available
Approval status,Chumakov Center CoviVac,Early use in Russia
,,
Developer(s),Gamaleya Gam-COVID-Vac/Sputnik V,Gamaleya Research Institute
Platform,Gamaleya Gam-COVID-Vac/Sputnik V,Non-replicating viral vector
Dosing,Gamaleya Gam-COVID-Vac/Sputnik V,"2 doses, intramuscular"
Description,Gamaleya Gam-COVID-Vac/Sputnik V,Recombinant Ad26 (prime) and recombinant Ad5 (boost) viruses expressing full-length spike (S) protein
Published results,Gamaleya Gam-COVID-Vac/Sputnik V,Phase I/II - see <b>Living review</b>
Efficacy data,Gamaleya Gam-COVID-Vac/Sputnik V,Vaccine efficacy against COVID-19 of 92% based on primary efficacy analysis of 78 confirmed cases - see <b>Living review</b>
Storage requirements,Gamaleya Gam-COVID-Vac/Sputnik V,Being produced in lyophilised formulation requiring refrigeration (2°C to 8°C) or frozen formulation (maximum -18°C)
"<a href=""https://www.one.org/international/vaccine-access-test/"" target=""_blank"">ONE Vaccine Access Test score</a>",Gamaleya Gam-COVID-Vac/Sputnik V,Sputnik V given score of 8 out of 20
Approval status,Gamaleya Gam-COVID-Vac/Sputnik V,"Early or emergency use in numerous countries, including Russia, Belarus, Argentina, Serbia, and Algeria"
,,
Developer(s),Finlay Soberana 02,Instituto Finlay de Vacunas Soberana 02
Platform,Finlay Soberana 02,Protein subunit
Dosing,Finlay Soberana 02,"2 or 3 doses, intramuscular"
Description,Finlay Soberana 02,RBD administered chemically conjugate to tetanus toxoid
Published results,Finlay Soberana 02,None
Efficacy data,Finlay Soberana 02,"Vaccine efficacy of 62% against COVID-19 based on press reports on <a href=""https://finance.yahoo.com/news/1-cuba-says-abdala-vaccine-000550749.html"" target=""_blank"">22 Jun 2021</a>); further details and full publication pending"
Storage requirements,Finlay Soberana 02,Pending - refrigeration (2°C to 8°C) is typical for protein subunit vaccines
"<a href=""https://www.one.org/international/vaccine-access-test/"" target=""_blank"">ONE Vaccine Access Test score</a>",Finlay Soberana 02,No score available
Approval status,Finlay Soberana 02,Early or emergency use in Cuba and Iran
,,
Developer(s),Janssen Ad26.COV2.S,Janssen Pharmaceutical Companies
Platform,Janssen Ad26.COV2.S,Non-replicating viral vector
Dosing,Janssen Ad26.COV2.S,"1 dose, intramuscular"
Description,Janssen Ad26.COV2.S,Ad26 vector expressing stabilised pre-fusion spike (S) protein
Published results,Janssen Ad26.COV2.S,Phase I/II/III - see <b>Living review</b>
Efficacy data,Janssen Ad26.COV2.S,Vaccine efficacy against COVID-19 of 67% after single dose based on primary efficacy analysis of 464 confirmed cases - see <b>Living review</b>
Storage requirements,Janssen Ad26.COV2.S,Refrigeration (2°C to 8°C)
"<a href=""https://www.one.org/international/vaccine-access-test/"" target=""_blank"">ONE Vaccine Access Test score</a>",Janssen Ad26.COV2.S,Johnson & Johnson given score of 9 out of 20
Approval status,Janssen Ad26.COV2.S,"Early or emergency use in South Africa, Bahrain, and USA; granted emergency use approval by the WHO on <a href=""https://extranet.who.int/pqweb/vaccines/who-recommendation-janssen-cilag-international-nv-belgium-covid-19-vaccine-ad26cov2-s"" target=""_blank"">12 Mar 2021</a>"
,,
Developer(s),Medigen MVC-COV1901,"Medigen Vaccine Biologics Corporation, NIAID, Dynavax"
Platform,Medigen MVC-COV1901,Protein subunit
Dosing,Medigen MVC-COV1901,"2 doses, intramuscular"
Description,Medigen MVC-COV1901,Recombinant stabilised prefusion spike (S) protein vaccine adjuvanted with CpG 1018 (Dynavax) and aluminum hydroxide
Published results,Medigen MVC-COV1901,Phase I - see <b>Living review</b>
Efficacy data,Medigen MVC-COV1901,Pending
Storage requirements,Medigen MVC-COV1901,Pending - refrigeration (2°C to 8°C) is typical for protein subunit vaccines
"<a href=""https://www.one.org/international/vaccine-access-test/"" target=""_blank"">ONE Vaccine Access Test score</a>",Medigen MVC-COV1901,No score available
Approval status,Medigen MVC-COV1901,Emergency use in Taiwan
,,
Developer(s),Moderna mRNA-1273,"Moderna, NIAID"
Platform,Moderna mRNA-1273,RNA
Dosing,Moderna mRNA-1273,"2 doses, intramuscular"
Description,Moderna mRNA-1273,Lipid nanoparticle-encapsulated mRNA encoding pre-fusion spike (S) protein
Published results,Moderna mRNA-1273,Phase I/II/III - see <b>Living review</b>
Efficacy data,Moderna mRNA-1273,Vaccine efficacy against COVID-19 of 94% based on primary efficacy analysis of 196 confirmed cases - see <b>Living review</b>
Storage requirements,Moderna mRNA-1273,Refrigeration (2°C to 8°C) for up to 30 days or frozen (-15°C to -25°C) for long-term storage
"<a href=""https://www.one.org/international/vaccine-access-test/"" target=""_blank"">ONE Vaccine Access Test score</a>",Moderna mRNA-1273,Moderna given score of 5 out of 20
Approval status,Moderna mRNA-1273,"Full or emergency use in numerous countries, including USA, Canada, EU, UK, and Israel; granted emergency use approval by the WHO on <a href=""https://extranet.who.int/pqweb/vaccines/covid-19-mrna-vaccine-nucleoside-modified"" target=""_blank"">30 Apr 2021</a>"
,,
Developer(s),Oxford/AstraZeneca ChAdOx1-S,"University of Oxford, AstraZeneca"
Platform,Oxford/AstraZeneca ChAdOx1-S,Non-replicating viral vector
Dosing,Oxford/AstraZeneca ChAdOx1-S,"2 doses, intramuscular"
Description,Oxford/AstraZeneca ChAdOx1-S,Simian adenovirus vector containing codon-optimised spike (S) protein
Published results,Oxford/AstraZeneca ChAdOx1-S,Phase I/II/III - see <b>Living review</b>
Efficacy data,Oxford/AstraZeneca ChAdOx1-S,Vaccine efficacy against COVID-19 reported to be 62–90% based on interim data from 131 cases - see <b>Living review</b>
Storage requirements,Oxford/AstraZeneca ChAdOx1-S,Refrigeration (2°C to 8°C)
"<a href=""https://www.one.org/international/vaccine-access-test/"" target=""_blank"">ONE Vaccine Access Test score</a>",Oxford/AstraZeneca ChAdOx1-S,AstraZeneca given score of 7 out of 20
Approval status,Oxford/AstraZeneca ChAdOx1-S,"Emergency use in numerous countries, including UK, EU, India, Argentina, Dominican Republic, and El Salvador; granted emergency use approval by the WHO on <a href=""https://extranet.who.int/pqweb/vaccines/covid-19-vaccine-chadox1-s-recombinant"" target=""_blank"">15 Feb 2021</a>"
,,
Developer(s),Research Institute for Biological Safety Problems QazCovid-in,"Research Institute for Biological Safety Problems, Kazakhstan"
Platform,Research Institute for Biological Safety Problems QazCovid-in,Inactivated
Dosing,Research Institute for Biological Safety Problems QazCovid-in,"2 doses, intramuscular"
Description,Research Institute for Biological Safety Problems QazCovid-in,Inactivated vaccine adiministered with aluminium hydroxide adjuvant
Published results,Research Institute for Biological Safety Problems QazCovid-in,None
Efficacy data,Research Institute for Biological Safety Problems QazCovid-in,Pending
Storage requirements,Research Institute for Biological Safety Problems QazCovid-in,Pending - refrigeration (2°C to 8°C) is typical for inactivated vaccines
"<a href=""https://www.one.org/international/vaccine-access-test/"" target=""_blank"">ONE Vaccine Access Test score</a>",Research Institute for Biological Safety Problems QazCovid-in,No score available
Approval status,Research Institute for Biological Safety Problems QazCovid-in,Early use in Kazakhstan
,,
Developer(s),Shenzhen Kangtai KCONVAC,Shenzhen Kangtai Biological Products Co Ltd
Platform,Shenzhen Kangtai KCONVAC,Inactivated
Dosing,Shenzhen Kangtai KCONVAC,"2 doses, intramuscular"
Description,Shenzhen Kangtai KCONVAC,Inactivated vaccine administered with aluminium hydroxide adjuvant
Published results,Shenzhen Kangtai KCONVAC,Phase I/II - see <b>Living review</b>
Efficacy data,Shenzhen Kangtai KCONVAC,Pending
Storage requirements,Shenzhen Kangtai KCONVAC,Pending - refrigeration (2°C to 8°C) is typical for inactivated vaccines
"<a href=""https://www.one.org/international/vaccine-access-test/"" target=""_blank"">ONE Vaccine Access Test score</a>",Shenzhen Kangtai KCONVAC,No score available
Approval status,Shenzhen Kangtai KCONVAC,Emergency use in China
,,
Developer(s),Shifa Pharmed COVIran,Shifa Pharmed
Platform,Shifa Pharmed COVIran,Inactivated
Dosing,Shifa Pharmed COVIran,"2 doses, intramuscular"
Description,Shifa Pharmed COVIran,Inactivated vaccine adiministered with aluminium hydroxide adjuvant
Published results,Shifa Pharmed COVIran,None
Efficacy data,Shifa Pharmed COVIran,Pending
Storage requirements,Shifa Pharmed COVIran,Pending - refrigeration (2°C to 8°C) is typical for inactivated vaccines
"<a href=""https://www.one.org/international/vaccine-access-test/"" target=""_blank"">ONE Vaccine Access Test score</a>",Shifa Pharmed COVIran,No score available
Approval status,Shifa Pharmed COVIran,Emergency use in Iran
,,
Developer(s),Sinovac CoronaVac,Sinovac
Platform,Sinovac CoronaVac,Inactivated
Dosing,Sinovac CoronaVac,"2 doses, intramuscular"
Description,Sinovac CoronaVac,Inactivated vaccine adiministered 
Published results,Sinovac CoronaVac,Phase I/II - see <b>Living review</b>
Efficacy data,Sinovac CoronaVac,"Vaccine efficacy against COVID-19 reported to be 50% in a press release on <a href=""http://www.sinovac.com/?optionid=754&auto_id=927"" target=""_blank"">03 Apr 2021</a>); estimates based on 85 confirmed cases from phase III trial in Brazil; in Turkey, vaccine efficacy was reported to be 91% but no furter details are currently available"
Storage requirements,Sinovac CoronaVac,Refrigeration (2°C to 8°C)
"<a href=""https://www.one.org/international/vaccine-access-test/"" target=""_blank"">ONE Vaccine Access Test score</a>",Sinovac CoronaVac,No score available
Approval status,Sinovac CoronaVac,"Full or emergency use in numerous countries, including China, Azerbaijan, Brazil, Chile, and Colombia"
,,
Developer(s),Vector Institute EpiVacCorona,Vector Institute
Platform,Vector Institute EpiVacCorona,Protein subunit
Dosing,Vector Institute EpiVacCorona,"2 doses, intramuscular"
Description,Vector Institute EpiVacCorona,Peptide antigens conjugated to a carrier protein and administered with aluminum hydroxide
Published results,Vector Institute EpiVacCorona,Phase I/II - see <b>Living review</b>
Efficacy data,Vector Institute EpiVacCorona,Pending
Storage requirements,Vector Institute EpiVacCorona,Pending - refrigeration (2°C to 8°C) is typical for protein subunit vaccines
"<a href=""https://www.one.org/international/vaccine-access-test/"" target=""_blank"">ONE Vaccine Access Test score</a>",Vector Institute EpiVacCorona,No score available
Approval status,Vector Institute EpiVacCorona,Early use in Russia
,,
Developer(s),Wuhan/Sinopharm vaccine,"Wuhan Institute of Biological Products, Sinopharm"
Platform,Wuhan/Sinopharm vaccine,Inactivated
Dosing,Wuhan/Sinopharm vaccine,"2 doses, intramuscular"
Description,Wuhan/Sinopharm vaccine,Inactivated vaccine adsorbed to 0.5-mg alum
Published results,Wuhan/Sinopharm vaccine,Phase I/II - see <b>Living review</b>
Efficacy data,Wuhan/Sinopharm vaccine,Vaccine efficacy against COVID-19 of 73% based on interim efficacy analysis of 121 confirmed cases - see <b>Living review</b>
Storage requirements,Wuhan/Sinopharm vaccine,Refrigeration (2°C to 8°C)
"<a href=""https://www.one.org/international/vaccine-access-test/"" target=""_blank"">ONE Vaccine Access Test score</a>",Wuhan/Sinopharm vaccine,No score available
Approval status,Wuhan/Sinopharm vaccine,Limited use in China and UAE